pharmaphorum March 12, 2025
MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to produce the bulk drug substance for its HPV vaccine Gardasil.
The 225,000 sq. ft. plant – which is dedicated to vaccines production – is part of a broader $12 billion capital investment that MSD has made in its manufacturing capacity since 2018, with another $8 billion planned between now and 2028.
While the announcement of the opening comes at an opportune time for MSD (known as Merck & Co in the US and Canada), given President Trump’s strident calls for more pharma manufacturing to be located within the US, the additional capacity for Gardasil comes at a...
Today's Sponsors
Today's Sponsor